Winnipeg Regional Health Authority, Health Sciences Centre, Winnipeg Diabetes Research Group, Department of Medicine, Section of Endocrinology, University of Manitoba, Winnipeg, Manitoba, Canada.
Winnipeg Regional Health Authority, Health Sciences Centre, Winnipeg Diabetes Research Group, Department of Medicine, Section of Endocrinology, University of Manitoba, Winnipeg, Manitoba, Canada.
Can J Diabetes. 2015 Apr;39(2):146-51. doi: 10.1016/j.jcjd.2014.10.003. Epub 2015 Jan 23.
A Canadian survey was undertaken to elucidate injection techniques in the population of the country with diabetes and to make appropriate revisions to the 2011 Canadian Forum for Injection Technique recommendations.
The study involved 503 participants (25% with type 1 diabetes; 75% with type 2 diabetes) from 55 diabetes education centres across Canada. They completed a survey regarding injection technique (i.e. needle length, angle of insertion, incidence of lipohypertrophy, injection routine). Healthcare professionals at the centres also completed a survey regarding their patients' injection techniques. To be eligible for the study, participants had injected either insulin or a glucagon-like peptide-1 receptor agonist for at least 6 months prior to enrolment.
Varying lengths of needles were used for injections; however, 45.3% of participants had changed needle lengths since they had begun injecting. The vast majority of participants (80.4%) injected medication into the abdomen; 36.6% had no explicit injection routine, whereas 31.4% injected into the same site at the same time each day. Overall, 24.6% of patients observed lipohypertrophy at injection sites, while only 13.3% of diabetes educators observed the same complication.
The survey allowed for a greater understanding of the strengths and weaknesses of Canadian patients and clinicians in the treatment of diabetes, particularly with respect to injection practices and procedures.
加拿大开展了一项调查,旨在阐明该国糖尿病患者的注射技术,并对 2011 年加拿大注射技术论坛的建议进行适当修订。
该研究涉及来自加拿大 55 个糖尿病教育中心的 503 名参与者(25%为 1 型糖尿病患者;75%为 2 型糖尿病患者)。他们完成了一份关于注射技术(即针头长度、插入角度、脂肪增生发生率、注射常规)的调查。中心的医疗保健专业人员也完成了一份关于其患者注射技术的调查。为了有资格参加研究,参与者在入组前至少已经注射胰岛素或胰高血糖素样肽-1 受体激动剂 6 个月。
不同长度的针头用于注射;然而,45.3%的参与者自开始注射以来已经改变了针头长度。绝大多数参与者(80.4%)将药物注射到腹部;36.6%没有明确的注射常规,而 31.4%每天在同一部位同一时间注射。总体而言,24.6%的患者在注射部位观察到脂肪增生,而只有 13.3%的糖尿病教育者观察到同样的并发症。
该调查使我们更好地了解了加拿大患者和临床医生在治疗糖尿病方面的优势和不足,特别是在注射实践和程序方面。